info@affiniatx.com
43 Foundry Ave, Suite 120 Waltham, MA 02453

We see what’s possible tomorrow for patients by creating it today

Our purpose is to make a lasting positive impact on the lives of those affected by devastating diseases.

Read Our Story

We are drug developers and creators. We are Affinians

We are a team with decades of proven success in translating science from bench to bedside across many companies and medicines. We’re using our deep expertise to set a new standard in gene therapy.

Meet Our Team

We are the next generation of gene therapies

There’s a new frontier in the fight against devastating rare and prevalent diseases, and Affinia Therapeutics is pioneering the way. We’re expanding what’s possible with adeno-associated virus (AAV) gene therapy, starting with diseases of the heart and of the nervous system.

Explore Our Pipeline

We are breakthrough science

We’ve employed AI and structural modeling to rationally design novel capsids to deliver therapeutic cargoes – ones that better target tissues and so, may improve safety and effectiveness. Our first program AFTX-201 is for a devastating genetic disease of the heart: BAG3-associated dilated cardiomyopathy. We believe it could be transformative.

Explore Our Science

We are writing news every day

The work we do is innovative and newsworthy. It’s covered in leading scientific and industry conferences and journals.

Read Our News

Our Pipeline

Read More

Our Platform

Take a look at what sets Affinians apart
Read More

Learn more about the building blocks of a gene therapy

Read More

We see what’s possible tomorrow by creating it today

There’s a new frontier in the fight against devastating rare and prevalent diseases, and Affinia Therapeutics is leading the way. We’re expanding what’s possible in adeno‑associated virus (AAV) gene therapy today to bring transformative medicines for people in need tomorrow.

Read Our Story
Affinia_Sept-2024_HP_1200x900
home page - 2
home page - 3 (1)

Developing therapies
with breakthrough
rational design science

With our proprietary ART: Affinia Rationally-designed Therapies platform we generate a deep understanding of how structure impacts function to rationally design the gene therapies of tomorrow.

Explore Our Science
LATEST NEWS

Read our latest news

June 3, 2025

Affinia Therapeutics and DCM Foundation Announce Partnership to Increase Awareness About BAG3 Dilated Cardiomyopathy and Critical Need for Genetic Testing to Help Save Lives

Affinia Therapeutics Appoints Hideo Makimura, M.D., Ph.D., as Chief Medical Officer
View More
May 19, 2025

ASGCT 2025: Development of a Flexible High Yielding, High Performing Process for Manufacturing of AFTX-201, a Novel Investigational AAV Gene Therapy for Treatment of BAG3 Dilated Cardiomyopathy

View More
May 19, 2025

ASGCT 2025: A Novel Investigational AAV Gene Therapy for Treatment of BAG3 Dilated Cardiomyopathy

View More
View All News

Contact Info

info@affiniatx.com

Office Address

Affinia Therapeutic
43 Foundry Ave, Suite 120 Waltham, MA 02453
Linkedin-in